Myositis-specific antibodies (MSAs) are associated with certain symptoms in JM patients. In some cases, knowing the MSA of a patient may help clinicians look out for certain symptoms and guide treatment decisions. Dr. Jessica Neely explains these associations, why they are important, and the limitations in our understanding of the role of MSAs in JM.
Research is vital to finding better treatments and a cure for juvenile myositis. Cure JM funds research studies through our Cure JM Centers of Excellence and the Cure JM Clinical Care Network.
Featuring Jim Minow, Executive Director of Cure JM, Dr. Andrew Heaton, Ph.D, Chief Scientific Officer, and Shannon Malloy, Director of Development and Family Engagement.
The following brochures, handouts and posters are available for online viewing and printing. If you need professionally printed copies for an event, please contact us.
The Cure JM Foundation produces a monthly newsletter with the latest news and updates about Juvenile Myositis. Please click below to read past issues of the Family News. Read the Newsletter Family News: October 2022 Family News: September 2022 Family News: August 2022 Family News: July 2022 Family News: June 2022
Cure JM has created resources and connections for over 4,000 patients and families in 40 different countries—including regional JM family support representatives throughout the U.S.
Kindergarten is about making friends, learning how to count by two’s, and reading Biscuit books. But for Madi, Kindergarten was not so simple.
Cure JM Foundation is a 501(c)(3) nonprofit, volunteer-managed organization dedicated to finding a cure for juvenile myositis (JM).
Cure JM was founded 19 years ago by a small group of volunteers who wanted to change the world for children with a rare disease few had ever heard of—juvenile myositis, or JM.
At age 4 Parker was diagnosed with juvenile dermatomyositis. Only 2 in a million children are affected. We started Cure JM to find a cure and help kids like Parker.